Megestrol Acetate NDC 71205-943

NDC codes

FDA NDC Directory

Product NDC (as listed)71205-943Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71205-0943Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71205-943-15	71205094315	150 mL in 1 BOTTLE (71205-943-15)Marketed from Nov 19, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Megestrol Acetate
Generic name (nonproprietary): megestrol acetate
Active ingredients: Megestrol acetate — 125 mg/mL
Dosage form: Suspension
Route: Oral
Labeler: Proficient Rx LP
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203139
Marketing start: Mar 1, 2015
Listing expires: Dec 31, 2026
Other FDA classes: Progesterone Congeners (Chemical structure)
Identifiers: Product ID 71205-943_e9000264-858a-4fcd-af09-21460169305dSPL ID e9000264-858a-4fcd-af09-21460169305dSPL set ID 6342df31-afce-4deb-b992-e08e2a4b2b77RxCUI 577154UNII TJ2M0FR8ESUPC 0371205943158
Pharmacologic class: Progestin

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471205094315 followed by a unit qualifier and the quantity

Package 71205-0943-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 1, 2022.

Indications (excerpt from the label)

Megestrol acetate oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Limitations of Use Therapy with megestrol acetate oral suspension for weight loss should only be insti‑tuted after treatable causes of weight loss are sought and addressed. These treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. Megestrol acetate oral suspension is not intended for prophylactic use to avoid weight loss. Megestrol acetate oral suspension is a progesti…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 203139

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203139
Product	Strength	Form · route	Labeler	Product NDC
Megestrol Acetate	Megestrol acetate 125 mg/mL	SuspensionOral	Upsher-Smith Laboratories, LLC	24979-041